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Abstract
Background: Studies on the association of total cholesterol (TC) levels and mortality in hemodialysis (HD) patients
demonstrated conflicting results. The differenct effect of Hypercholesterolemia on HD patients based on the
presence of myocardial infarction (MI) or coronary artery disease (CAD) is unknown.
Methods: We analyzed data from the Taiwan Renal Registry Data System (TWRDS) between 2005 and 2012.
Patients were divided into MI/CAD or non-MI/CAD group. The primary outcome was three-year mortality. The
association between primary outcome and first year average TC and effect of change in cholesterol level between the
first and third year of dialysis were explored.
Results: Of 90,795 HD patients, 77,762 (85.6%) patients were assigned to non-MI/CAD group and 13,033 (14.4%) to the
MI/CAD group. In the non-MI/CAD subjects, both TC > 250 mg/dL and < 150 mg/dL were associated with increased
risk of mortality (adjusted hazard ratio [HR]; 95% confidence interval [CI]: 1.27; 1.17–1.37 and 1.14; 1.11–1.18) compared
to the reference (TC: 150–200 mg/dL). In the MI/CAD patients, only TC < 150 mg/dL had increased risk (HR; 95% CI: 1.
15; 1.08–1.24). In addition, patients of the non-MI/CAD group with highest level of TC (>250 mg/dL) in both first and
third year of dialysis had a 64% increased risk for mortality (HR: 1.64, 95% CI: 1.51–1.80).
Conclusion: In this nationwide hemodialysis cohort, hypercholesterolemia was associated with increased mortality in
HD patients without MI/CAD. Further investigation on primary prevention of CAD with statin is warranted.
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Background
Chronic kidney disease (CKD) and end-stage renal dis-
ease (ESRD) are emerging epidemiological issues in the
world and have a high mortality rate. Cardiovascular dis-
ease (CVD) is the leading cause of mortality in this
population [1]. In general, high cholesterol level is an
important precipitating factor affecting atherosclerotic
arterial wall changes and causing CVD, starting in young
age [2] and is associated with higher mortality rates in
many prospective studies [3]. In patients with ESRD,
lipoprotein metabolism is also dysregulated. For ex-
ample, reduced high-density lipoprotein cholesterol
(HDL), increased plasma triglyceride (TG) concentra-
tions, defect in cholesterol transport, and the increase in
atherogenic small dense low-density lipoprotein choles-
terol (sdLDL) subclass are common in ESRD patients
[4]. Despite lipoprotein dysregulation in HD patients,
high cholesterol level in dialysis patients is paradoxically
associated with higher survival rates, according to
several observational studies [5, 6].
The role of hypercholesterolemia varies between dif-
ferent subgroups of dialysis patients. According to a
large population study from Japan renal data registry,
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although the onset of myocardial infarction is associated
with dyslipidemia, for those who had CVD, the death
after events is not positively associated with non-HDL
cholesterol level [7]. Therefore, we aim to investigate
whether the association between serum total cholesterol
(TC) level and all-cause mortality would be altered in
HD patients by the presence of myocardial infarction or
coronary artery disease.
Methods
This study was approved by the ethics committee of
Taipei Medical University’s institutional review board
(Number: N201506012), and was conducted in accord-
ance with the principles of the Declaration of Helsinki.
The institutional review board of Taipei Medical University
approved the waiver of informed consent.
The Taiwan renal registry data system
The Taiwan Renal Registry Data system (TWRDS) was
built in 1987 initially for the accreditation of dialysis
therapy. All dialysis units in Taiwan are required to pro-
vide the appropriate laboratory and clinical information
for inclusion in the TWRDS to obtain national health in-
surance (NHI)-associated reimbursements. Every dialysis
unit submits a quarterly laboratory report. In 1997, add-
itional data were gathered, including those relating to
co-morbidities such as the history of myocardial infarc-
tion (MI), coronary artery disease (CAD), the patients’
rehabilitation statuses, the dialysis adequacy indices,
biochemical and hematological parameters, the hepatitis
serological results, prescription of anti-hypertension medi-
cations or not, anemia management, and mineral bone in-
dices [8]. Because dialysis expenses are reimbursed to
each individual in full amount, the application for main-
tenance of dialysis certification is processed after review of
the medical records by a senior physician and uploaded to
the system. Another senior nephrologist gives the ap-
proval of reimbursement from NHI bureau. Presence of
MI or CAD was defined as per the medical record docu-
mentation (history of percutaneous transluminal coronary
angioplasty, coronary artery bypass grafting, computed
tomography angiography, acute coronary syndrome…etc.)
of each individual. The Taiwan Renal Registry Data system
provide reliable information and data for the continual
survaliance and quality control of dialysis at the nation-
wide level [9–12]. We analyzed the data in the TWRDS
database that was generated between 2005 and 2012.
Patient enrollment and study design
Patients registered with the TWRDS from 2005 to 2012
were included in the analysis (N = 102,599). After ex-
cluding patients who had changed their dialysis modality
(N = 927), had concurrent malignant tumor (N = 7162),
are age younger than 20 or older than 90 years old
(N = 998), and without cholesterol data (N = 2717),
the final sample that went forward for analysis com-
prised of 90,795 patients. Among them, 13,033 pa-
tients (14.4%) had MI or CAD (MI/CAD group), and
77,762 (85.6%) patients identified as without MI or
CAD (non-MI/CAD group) were included in analysis
(Fig. 1). The primary endpoint of this study was the
3-year all-cause mortality rate. An individual was
regarded dead if he or she was lost to follow-up in
the TWRDS based on the complete national coverage
provided by the NHI policy for all renal replacement
therapy expenditures. Patients were categorized into 4
groups by the first year average cholesterol level
(<150, 150–200, 200–250, > 250 mg/dL) according to
the definition of hypercholesteremia from The National
Cholesterol Education Program and the definition of mal-
nutrition in HD patients from the NKF KDOQI guidelines
[13]. We also assessed the effect of change in cholesterol
level on mortality during the first three years of dialysis.
Nine groups were created on the basis of total cholesterol
(TC) (<150, 150–250, > 250 mg/dL) in the first and third
year of dialysis.
Data extraction
The biochemical data of hemodialysis patients in
TWRDS 2005–2012, including TC and fasting TG, fast-
ing glucose, albumin, hematocrit (Hct), white blood cell
(WBC) counts, calcium (Ca), phosphorus (P), alkaline
phosphatase (Alk-P) and intact parathyroid hormone
(i-PTH) were collected every 3 months. Fasting blood
samples were drawn before dialysis. About 80% of the
Final study population,
N=90795
Once shifting dialysis 
between HD/PD, N=927
History of malignant tumor,
N=7162











Without history of myocardial 
infarction or conorary artery 
disease,
N=77762
With history of myocardial 
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N=13033
Fig. 1 Flow chart of patient enrollment
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samples were sent to Union Clinical Laboratory. En-
zymatic methods on a Siemens (Munich, Germany)
autoanalyzer (ADVIA 1800) were used to determine
general chemistry including cholesterol (coefficient of
variation [CV] 1.1%). The average of four measure-
ments of cholesterol levels in the first year was used
as the baseline value to predict patient survival. Car-
diomegaly was defined by chest thoracic ratio more
than 0.5 on chest plain radiography.
Statistical analysis
The descriptive statistics were expressed as the means
(standard deviations [SD]), medians (ranges), or frequen-
cies (percentages) for continuous variables and propor-
tions for categorical variables. One-way ANOVA test or
Kruskal Wallis test was used for the analysis of continu-
ous variables as appropriate, and the differences between
nominal variables were compared by the chi-square test.
Log-rank test was used for Kaplan-Meier analysis. The
level of significance was set at 0.05, two-tailed for all
tests.. We performed Cox regression analysis to estimate
the hazard ratios (HR) of 3-year mortality in HD patients
for different cholesterol level. The case-mix adjusted
model included the following confounding factors: age,
gender, the presence of diabetes mellitus (DM), hyperten-
sion (HTN), congestive heart failure (CHF), cardiomegaly,
cerebral vascular accident (CVA), and the use of anti-
hypertensive agents or not. The laboratory data of glucose,
Hct, Ca, P, HD treatment adequacy score (the single-pool
Kt/V), and malnutrition/inflammation markers, including
albumin level and WBC counts were also adjusted in Cox
regression analysis. All of the descriptive and multivariate
analyses were performed using the Statistical Package for
the Social Sciences software version 17.0 for Windows XP




Baseline characteristics of the two groups categorized by
cholesterol level
Table 1 summarizes the study population’s baseline char-
acteristics categorized by with or without MI or CAD. A
total of 77,762 (85.6%) HD patients without MI or CAD
were identified and 13033 of the whole cohort as with
MI or CAD. The mean (SD) age of the patients was 61.9
[14] years. Type 2 diabetes mellitus was present in 52%
of the whole cohort. Patients without MI or CAD had
younger age, significant less comorbidities including
DM, HTN, CHF, cardiomegaly and CVA (Table 1).
Survival analysis: Kaplan-Meier survival curve
Figure 2 showed an overall unadjusted Kaplan-Meier
survival curve. In patients without MI or CAD (Fig. 2a),
the group with TC < 150 mg/dL had the worst survival rate,
followed by those groups with TC > 250, 150–200, and
200–250 mg/dL (Log rank, P < 0.001), respectively. In pa-
tients with CAD (Fig. 2b), the group with TC < 150 mg/dL
had the worst survival rate, followed by the group with TC
150–200 mg/dL, whereas the group with TC > 200 mg/dL
had the best survival rate (Log rank, P < 0.001).
Cox regression model for cholesterol level and mortality
Table 2 showed the crude and adjusted HR of mortal-
ity associated with total cholesterol in the Cox regres-
sion model. Case mix and malnutrition/inflammation
markers, including WBC counts and albumin levels
were adjusted. In the population without MI or CAD,
compared to the group of TC between 150–200 mg/dL,
the adjusted HRs were statistically significant, which are
1.27 (95% confidence interval [CI]: 1.17–1.37) and 1.14
(95% CI: 1.11–1.18) in the groups of TC > 250 mg/dL and
< 150 mg/dL, respectively. In the patients with CAD, sig-
nificant increase in HR (1.15, 95% CI: 1.08–1.24) was ob-
served in the group of TC < 150 mg/dL compared to the
Table 1 Baseline characteristics of 90,795 patients with
hemodialysis by presence of MI and CAD





Number 90795 77762 13033
Age (years) 61.9 ± 14 61.7 ± 14 63.4 ± 12 <0.0001
Male (%) 45634 (50%) 38817 (50%) 6817 (52%) <0.0001
DM (%) 47173 (52%) 38501 (50%) 8672 (67%) <0.0001
HTN (%) 39853 (44%) 30481 (39%) 9372 (72%) <0.0001
CHF (%) 12222 (13%) 7757 (10%) 4465 (34%) <0.0001
Cardiomegaly (%) 12027 (13%) 7896 (10%) 4131 (32%) <0.0001
CVA (%) 7090 (8%) 5082 (7%) 2008 (15%) <0.0001
HTN drugs (%) 49699 (55%) 40683 (52%) 9016 (69%) <0.0001
Laboratory data
WBC (x1000/uL) 7.1 ± 3.0 7.1 ± 3.1 7.1 ± 2.1 0.2515
TC (mg/dL) 171.8 ± 37.3 171.4 ± 37.3 174.2 ± 37.1 <0.0001
TG (mg/dL) 164.6 ± 106.5 162.2 ± 104.9 178.6 ± 114.9 <0.0001
Glucose (mg/dL) 148.5 ± 67.6 146.9 ± 67.5 157.5 ± 67.7 <0.0001
Albumin (g/dL) 3.8 ± 0.4 3.8 ± 0.4 3.8 ± 0.4 <0.0001
Hct (%) 30.6 ± 3.3 30.6 ± 3.4 30.8 ± 3.2 <0.0001
Ca (mg/dL) 9.2 ± 0.8 9.2 ± 0.8 9.2 ± 0.7 <0.0001
P (mg/dL) 4.9 ± 1.3 4.9 ± 1.3 4.9 ± 1.2 0.0002
ALK-P (u/L) 120.3 ± 96.9 121.0 ± 98.1 116.3 ± 89.6 <0.0001
i-PTH (pg/mL) 199.1 ± 185.7 200.4 ± 186.9 191.5 ± 178.6 <0.0001
Ca*P 44.6 ± 12.5 44.5 ± 12.6 45.2 ± 12.3 <0.0001
Abbreviations: HD hemodialysis, MI myocardial infarction, CAD coronary artery
disease, DM diabetes mellitus, HTN hypertension, CHF congestive heart failure,
CVA cerebral vascular accident, WBC white blood cells, TC total cholesterol, TG
triglyceride, Hct hematocrit, Ca calcium, P phosphorus, Alk-P alkaline
phosphatase, iPTH intact parathyroid hormone
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reference group of TC 150–200 mg/dL. Figure 3 showed
the curve of crude and adjusted HR of TC levels in non-
MI/CAD and MI/CAD groups. An inverse association be-
tween TC and HR of all-cause mortality was observed in
the MI/CAD group (Fig. 3b), while a U-curve was ob-
served in the non-MI/CAD group with a significantly
higher HR when TC was > 250 mg/dL or < 150 mg/dL
(Fig. 3a).
Mortality and cholesterol level between the first year and
the third year
Relative risk for mortality based on the change in choles-
terol level between the first and third year of dialysis is
shown in Table 3. In patients in non-MI/CAD group,
the level of TC >250 mg/dL between first and third year
of dialysis, showed a significant higher mortality risk
(HR: 1.64, 95% CI: 1.51–1.80) compared with normal
Fig. 2 Unadjusted survival curve by total cholesterol level in HD patients. a without MI or CAD. b with MI or CAD
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TC level (150–250 mg/dL). The lowest level of TC in
the first and third year of dialysis, irrespective of MI/
CAD in the patient, had the highest HR (non MI/CAD
group, HR: 1.76, 95% CI: 1.71–1.80; MI/CAD group,
HR: 1.55, 95% CI: 1.45–1.65;) compared to the levels in
reference group.
Discussion
In this nationwide, population based study, we demon-
strated that in patients under maintenance hemodialysis,
different patterns of association between TC and mortality
exist. In those without MI/CAD, an increased mortality
was observed when TC is higher than 250 mg/dL. In
addition, patients without MI/CAD who had TC levels >
250 mg/dL in the first and third years had a 64% increased
risk for mortality.
Although CV mortality was significantly higher in pa-
tients under dialysis compared with the general popula-
tion [14], the correlation of TC values with the major
outcomes in the HD subgroups showed conflicting
Table 2 Hazard ratio (95% CI) for mortality associated with total cholesterol level
Without MI or CAD (N = 77762) With MI or CAD (N = 13033)
TC (mg/dL) (N) Median (25th-75th)
of TC (mg/dL)
Crude HR Adjusted HR** TC (mg/dL) (N) Median (25th-75th)
of TC (mg/dL)
Crude HR Adjusted HR**
<150 (22987) 133 (121–142) 1.51 (1.47–1.55)* 1.14 (1.11–1.18)* <150 (3473) 135 (123–143) 1.34 (1.26–1.43)* 1.15 (1.08–1.24)*
150–200 (38505) 173 (162–185) 1.00 1.00 150–200 (6607) 173 (162–186) 1.00 1.00
200–250 (14295) 215 (207–227) 0.88 (0.85–0.91)* 0.99 (0.96–1.03) 200–250 (2559) 215 (207–228) 0.88 (0.82–0.95) 0.97 (0.89–1.04)
>250 (1975) 266 (257–285) 1.14 (1.07–1.22)* 1.27 (1.17–1.37)* >250 (394) 267 (257–283) 0.89 (0.72–1.03) 1.09 (0.92–1.30)
Abbreviations: CI confidence interval, MI myocardial infarction, CAD coronary artery diease, TC total cholesterol, HR hazard ratio
*p < 0.01; **adjusted for age, gender, history of DM、HTN、cardiomegaly、CVA, levels of hematocrit, calcium, phosphorus, parathyroid hormone, alkaline
phosphatase, Kt/V, albumin and white blood cell counts
Fig. 3 Hazard ratios of mortality by total cholesterol level in HD patients. a without MI or CAD. b with MI or CAD
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results. There are no studies that compared the differen-
tial influence of lipoproteins on HD patients with regard
to the presence of MI or CAD. Patients with previous
CAD were more likely to receive statins and other anti-
platelet medication such as aspirin, which have a pro-
tective effect could be one of the confounding factors. A
study by Shoji et al. including 45,390 HD patients from
Japan renal registry reported that non-HDL was associ-
ated with increased risk of CVD incidents, but the mor-
tality after new onset of CAD was not associated with
dyslipidemia [7].
The positive correlation of cholesterol and mortality
when TC is above 250 mg/dL in the group of HD with-
out previous MI/CAD is similar to that in the general
population. Despite that only a few individuals with total
cholesterol > 250 mg/dL (N = 1975 and 394 in non-MI/
CAD and MI/CAD groups seperately) are on regular
HD, the mortality still correlated with the higher TC
levels in those without previous MI history. In the gen-
eral population, statin therapy for lipid-lowering is fun-
damental and “the lower the better” is the strategy for
many physicians. According to the current KDIGO
guideline, lipid-lowering agents such as statins should be
used for all CKD patients with high CVD risk [15]. How-
ever, the lipid-lowering agents are under-prescribed for
CKD patients than non-CKD patients with dyslipidemia
in clinical practice [16]. The results of large randomized
clinical trials (4D, AURORA, SHARP) on cardiovascular
benefits of LDL lowering therapy in HD patients have
been inconclusive [17–20]. The benefit of lowering serum
LDL cholesterol could be achieved only after 3 to 5 years
of statin therapy [21]. Therefore, the initiation of statins is
no longer recommended in dialysis patients [22]. In the
SHARP study which excluded patients with history of
coronary artery disease [19], it showed beneficial effect in
reducing major atherosclerotic events by reducing LDL
levels with daily simvastatin 20 mg plus ezetimibe 10 mg.
In our study, we found a U-curve relation between TC
and mortality in HD patients without MI or CAD from a
large population dataset which indicates that cholesterol
lowering therapy might be beneficial, but the goal and
candidate of treatment may not be the same as the non-
dialysis patients with high CV risk.
Although a large body of evidence suggests the posi-
tive correlation of TC with mortality in general popula-
tion [3], this correlation does not always exist in patients
with HD. Some authors proposed the reverse epidemi-
ology concept, where lower cholesterol is associated with
worsened CVD outcome by itself or maybe confounded
by malnutrition or inflammation when individual is on
maintenance dialysis therapy [5, 6]. Dialysis patients with
hypoalbuminemia interplayed with malnutrition that led
to proinflammatory condition and cytokine activation,
which is suggested to have higher prevalence in cardio-
vascular diseases [23–25]. There are other possible
explanations of reverse epidemiology other than malnu-
trition inflammation complex syndrome (MICS). Since
these dialysis patients underwent special selection for
renal replacement therapy and survived, they had sur-
vival bias and had different characteristics when com-
pared to the general population. Hypercholesterolemia
was not associated with increased mortality in HD pa-
tients with MI/CAD probably because the prevalence of
comorbidities was high. Moreover, HD patients with MI/
CAD tend to have shorter survival period, the harmful
insult from hyperlipidemia was considered in the long
term, which is not readily observed in this subgroup.
The association of low cholesterol with higher mortality
is also found in the group of chronic heart failure pa-
tients as in those with chronic renal failure [26]. The
possible explanation proposed is that lipoproteins may
potentially contribute to the reduction of endotoxin bio-
activity and consequently decrease cytokine production
[27–30]. It was also observed that cholesterol is a pro-
tective factor in patients with chronic disabling disease
or old age [31].
The relationship of cholesterol and mortality in HD pa-
tients was the same with general population in some ob-
servational study. Liu et al. reported in a prospective study
of 823 patients that in the absence of inflammation/mal-
nutrition, a positive correlation exists between cholesterol
and all-cause mortality [6]. However, in our study, the
markers of malnutrition and inflammation, albumin and
WBC counts, were found to be similar between MI/CAD
and non-MI/CAD group. After adjusted for these parame-
ters, TC level lower than 150 mg/dL still had an increased
risk for all-cause mortality in both MI/CAD and non-MI/
CAD group.
Table 3 Hazard ratio (95% CI) of all-cause mortality on HD patients
by changes in total cholesterol level (mg/dL) between 1st and 3rd
year
A. Without MI or CAD (N = 77762)
3rd year <150 150–250 >250
1st year
<150 1.76 (1.71–1.80)* * 0.75 (0.70–0.80) **
150–250 1.11 (1.05–1.18) * * 1.00 0.84 (0.67–1.04)
>250 0.88 (0.80–0.97)* 1.64 (1.51–1.80)**
B. With MI or CAD (N = 13033)
3rd year <150 150–250 >250
1st year
<150 1.55 (1.45–1.65)* * 0.93 (0.82–1.06)
150–250 1.20 (1.06–1.35) * * 1.00 0.69 (0.39–1.22)
>250 0.85 (0.70–1.03) 1.08 (0.85–1.38)
Abbeviations: CI confidence interval, HD hemodialysis, MI myocardial infarction,
CAD coronary artery diease
*p < 0.05, **p < 0.01
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Patients in the lowest cholesterol group in the first
year and the third year had the highest HR in the non-
MI/CAD or MI/CAD group, although the effect was
more significant in the non-MI/CAD group. This is
similar to the observation in non-demanding people
older than 70 years from a study of the Honolulu Heart
Program, in which the same patients being in the lowest
group of cholesterol from two examination periods had
the worst CV outcome [31]. However, patients without
previous MI/CAD who remained in the group of TC >
250 mg/dL in the first three years of dialysis showed a
64% increased risk in mortality in our study gave us a
hint that statin treatment maybe beneficial.
There were several limitations of this study. First,
there was no detailed data regarding anti-platelet, anti-
hypertension and most importantly, statin prescription
which may have effect on the mortality. The lower TC
level may have been due to the effect of medication.
However, it was noticed that even though the majority
of patients had TC level between 150 and 250 mg/dL, a
substantial proportion of the population had TC level <
150 mg/dL, with increased risk of mortality; this sug-
gests that the treatment goal should be TC <250 mg/dL
but not <150 mg/dL. Second, the actual cause of mortal-
ity can’t be identified from the TWRDS dataset. The
cause of death of patients with higher or lower total
cholesterol level maybe different in patients under main-
tenece dialysis and need further investigation. Third, the
lack of completeness of plasma lipoprotein profile in this
dataset was noted. However, we found there was no as-
sociation between plasma traiglyceride and all cause
mortality in this cohort (data not shown).
Conclusions
This nationwide population-based study showed hyper-
cholesterolemia was associated with increased mortality
in hemodialysis patients without MI/CAD. The effect of
hypercholesterolemia on mortality was not found in HD
patients with the presence of MI/CAD. Further studies
are warranted to confirm the benefit of early interven-
tion or monitoring of cholesterol level in HD patients
with different risk factors.
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